Imugene Limited (ASX:IMU)
Australia
· Delayed Price · Currency is AUD 0.230
-0.005 (-2.13%)
At close: Mar 9, 2026
Imugene Revenue
Imugene had revenue of 805.72K AUD in the half year ending December 31, 2025, a decrease of -90.01%. This brings the company's revenue in the last twelve months to 3.94M, down -314.40% year-over-year. In the fiscal year ending June 30, 2025, Imugene had annual revenue of 4.40M, down -11.53%.
Revenue (ttm)
3.94M
Revenue Growth
-314.40%
P/S Ratio
18.75
Revenue / Employee
262.94K
Employees
15
Market Cap
73.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.40M | -573.22K | -11.53% |
| Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
| Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
| Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
| Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alterity Therapeutics | 6.64M |
| Radiopharm Theranostics | 16.28M |
| Cynata Therapeutics | 1.69M |
| LTR Pharma | 1.13M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
Imugene News
- 3 months ago - Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours - PRNewsWire
- 8 months ago - Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PRNewsWire
- 2 years ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 2 years ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 2 years ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 2 years ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 2 years ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 4 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire